HAYWARD, Calif. / May 09, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company’s common stock at an... Read More

Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers Data, including overall survival (OS) and PFS, from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in... Read More

HAYWARD, Calif. / May 02, 2024 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. The fireside chat will take place on Thursday, May 16 th... Read More

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, and Lead Investigator for the EDGE-Gastric study Data from ARC-9 evaluating an etrumadenant plus zimberelimab-based... Read More

HAYWARD, Calif. / Apr 23, 2024 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8 th , 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline... Read More

HAYWARD, Calif. / Apr 09, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Mar 26, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Mar 11, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 13,800 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Feb 28, 2024 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Biopharma Conference 2024 Date: Monday, March 11 th , 2024 at 4:00 p.m. ET... Read More

HAYWARD, Calif. / Feb 27, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 17,600 shares of the Company’s common stock at an... Read More

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities Pharmacokinetic (PK), pharmacodynamic (PD), safety and early efficacy data, including initial observations from the expansion cohort, from ARC-20, support potential for casdatifan (AB521) to... Read More

HAYWARD, Calif. / Feb 09, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 71,900 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Feb 07, 2024 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial... Read More

HAYWARD, Calif. / Jan 26, 2024 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 76,700 shares of the Company’s common stock at an... Read More

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A 37% reduction in risk of death and a 5.9-month improvement in median overall survival was observed for patients treated with quemliclustat-based regimens when compared to a Synthetic Control Arm® (SCA®) of patients treated with... Read More

HAYWARD, Calif. / Dec 11, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Nov 27, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Nov 14, 2023 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6 th Annual Evercore ISI HealthCONx Conference in Miami, FL. The fireside chat will take place on Tuesday,... Read More

HAYWARD, Calif. / Nov 13, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an... Read More

Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Plenary Series; domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first-to-market for these cancers. Pharmacokinetic and pharmacodynamic data from the dose-escalation phase of ARC-20, a... Read More

HAYWARD, Calif. / Oct 24, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 4,800 shares of the Company’s common stock at an... Read More

Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line upper gastrointestinal cancers will be presented at the virtual ASCO Monthly Plenary Series by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center on November 7, 2023 Arcus Biosciences will also report third quarter 2023 results and host a... Read More

HAYWARD, Calif. / Oct 10, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 34,300 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Sep 26, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Sep 11, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 35,400 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Aug 24, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Aug 23, 2023 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference Date: Wednesday, September 6 th , 2023 at 10:15... Read More

HAYWARD, Calif. / Aug 09, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an... Read More

Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology (ASCO); Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measures evaluated, including progression-free survival, overall response rate, and duration of response Initiated the dose-expansion phase of... Read More

HAYWARD, Calif. / Jul 25, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Jul 11, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Jun 26, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 11,800 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Jun 09, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 11,600 shares of the Company’s common stock at an... Read More

Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy Results Will Be Presented Today During the American Society of Clinical Oncology (ASCO) Annual Meeting FOSTER CITY,... Read More

HAYWARD, Calif. / May 30, 2023 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in... Read More

HAYWARD, Calif. / May 24, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 53,800 shares of the Company’s common stock at an... Read More

Updated data from ARC-7, the randomized Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, will be presented in a special ASCO plenary series rapid abstract update session by Melissa L. Johnson, M.D., Director, Lung Cancer Research, Sarah Cannon Research Institute, and Lead Investigator for the ARC-7 study Presentation of multiple Phase 2 and Phase 3 trials in progress (TIP) highlight the company’s... Read More

Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort (100mg) of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma (ccRCC) patients are expected to begin in the third quarter. Three new... Read More

HAYWARD, Calif. / May 08, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,200 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Apr 25, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 17,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Apr 11, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 34,000 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Mar 09, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 66,200 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Mar 02, 2023 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Barclays Global Healthcare Conference in Miami Beach, Florida. The fireside chat will take place on Tuesday,... Read More

HAYWARD, Calif. / Feb 28, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting... Read More

HAYWARD, Calif. / Feb 24, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 7,000 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Feb 09, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 31,600 shares of the Company’s common stock at an... Read More

HAYWARD, Calif. / Feb 06, 2023 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events: SVB Securities Virtual Global Biopharma Conference Date: Tuesday, February 14 th ,... Read More

HAYWARD, Calif. / Jan 25, 2023 / Business Wire / Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 44,300 shares of the Company’s common stock at an exercise price per share of $22.02, which was the... Read More

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s common stock at an exercise price per share of $17.51, which was the closing price on January 9, 2023, and restricted stock... Read More

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted... Read More